Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorDJABAROUTI, S
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorMORA, P
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorLAHOUATI, M
dc.contributor.authorGIGAN, M
dc.contributor.authorD'HOUDAIN, N
dc.contributor.authorSOURISSEAU, B
dc.contributor.authorCHAMBORD, J
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorXUEREB, F
dc.date.accessioned2022-07-13T07:52:36Z
dc.date.available2022-07-13T07:52:36Z
dc.date.issued2022-07-01
dc.identifier.issn1768-3122en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140455
dc.description.abstractEnThe pharmacokinetics of drugs, such as immunosuppressants, justify the need of measuring their blood concentrations in order to adjust their dosage. Therapeutic Drug Monitoring (TDM) of ciclosporin, tacrolimus and mycophenolate mofetil has shown its benefit particularly in the management of renal transplantees, in order to prevent graft rejection. When prescribed in autoimmune diseases, their pharmacokinetic variability and the variability of clinical response would justify TDM in practice. TDM may be useful in systemic lupus, for hydroxychloroquine, in order to monitor patient compliance. Despite insufficient data in the literature, for mycophenolate mofetil, TDM would permit to maintain clinical remission in adults and children with lupus nephritis, as well as in mucosal pemphigoid and idiopathic nephrotic syndrome in children. Studies are still necessary to validate the thresholds and TDM conditions. For azathioprine, TPMT phenotyping is recommended before prescription. For methotrexate, tacrolimus and ciclosporin, data are still sparse on the benefit of TDM, although it may improve tolerance to tacrolimus in lupus. Finally, for infliximab, in case of loss of response in maintenance, TDM may be proposed in parallel with detection of anti-drug antibodies.
dc.language.isoENen_US
dc.subject.enAdult
dc.subject.enAutoimmune Diseases
dc.subject.enChild
dc.subject.enCyclosporine
dc.subject.enDrug Monitoring
dc.subject.enHumans
dc.subject.enImmunosuppressive Agents
dc.subject.enMycophenolic Acid
dc.subject.enTacrolimus
dc.title.en[Benefit of therapeutic drug monitoring of immunosuppressants and immunomodulators in the management of autoimmune diseases].
dc.title.alternativeRev Med Interneen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.revmed.2022.03.343en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed35643786en_US
bordeaux.journalLa Revue De Médecine Interneen_US
bordeaux.page412-418en_US
bordeaux.volume43en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-03722028
hal.version1
hal.date.transferred2022-07-13T07:52:49Z
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=La%20Revue%20De%20M%C3%A9decine%20Interne&rft.date=2022-07-01&rft.volume=43&rft.issue=7&rft.spage=412-418&rft.epage=412-418&rft.eissn=1768-3122&rft.issn=1768-3122&rft.au=DJABAROUTI,%20S&MORA,%20P&LAHOUATI,%20M&GIGAN,%20M&D'HOUDAIN,%20N&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée